OVOL1 targets YAP to suppress esophageal squamous cell carcinoma progression
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2026.112628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Zhaofang Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China; Guangxi Health Commission Key…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Transcription Factors, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province.
Abstract (Originalsprache)
BACKGROUND: Abnormal regulation of OVO-like proteins (OVOLs) has been recognized as an important contributor to cancer development. Ovo like transcriptional repressor 1 (OVOL1), a member of the OVOL family, has been reported to function either as a tumor suppressor or as an oncogene in different cancer types; however, its role in esophageal squamous cell carcinoma (ESCC) has not been clearly defined. METHODS: The expression of OVOL1 in ESCC was examined using multiple independent patient cohorts, and its clinical significance was further evaluated. The functional role of OVOL1 in ESCC cells was determined through both in vitro and in vivo experiments. To elucidate the underlying mechanisms, RNA-seq, luciferase reporter, co-immunoprecipitation, and chromatin immunoprecipitation (ChIP) assays were performed. RESULTS: Reduced OVOL1 expression was frequently observed across multiple ESCC cohorts and was associated with poor clinical outcomes. Both in vitro and in vivo experiments showed that enforced OVOL1 expression suppresses ESCC cell proliferation, stemness-associated traits, and lung metastasis caused by tail vein injection of ESCC cells in mice, whereas OVOL1 knockdown enhances these malignant behaviors. Mechanistically, OVOL1 represses Yes1-associated transcriptional regulator (YAP) transcription, which is likely achieved through a histone deacetylase (HDAC)-dependent mechanism, thereby limiting ESCC progression. CONCLUSION: OVOL1 acts as a tumor suppressor in ESCC, in part by suppressing YAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China; Guangxi Health Commission Key Laboratory of Tumor Immunology and Receptor-Targeted Drug Basic Resea…
- Department of Histology and Embryology, School of Preclinical Medicine, Guilin Medical University, Guilin, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
Zitieren
APA
Yan, Z., Li, Y., Li, J., Huang, S., Lan, H., Hu, G., Xie, C., Qi, G., & Gan, J. (2026). OVOL1 targets YAP to suppress esophageal squamous cell carcinoma progression. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112628
Vancouver
Yan Z, Li Y, Li J, Huang S, Lan H, Hu G, et al. OVOL1 targets YAP to suppress esophageal squamous cell carcinoma progression. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112628
BibTeX
@article{Yan2026,
author = {Yan, Zhaofang and Li, Yaqi and Li, Jinping and Huang, Shuxian and Lan, Hao and Hu, Genjian and Xie, Chichu and Qi, Guangying and Gan, Jinfeng},
title = {OVOL1 targets YAP to suppress esophageal squamous cell carcinoma progression},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2026.112628}
}
EUVIMED